Introduction: In 2004 we described the mutation E46K of the α-Synuclein (SNCA). These patients show Parkinson's disease with early cognitive impairment, sleep disorders and autonomic dysfunction.
Objective: The main objective is to identify early neuropsychological impairments in patients with the E46K mutation.
Methods: This is a longitudinal neuropsychological study of 4 of the 5 surviving patients with E46K mutation by semi-structured interviews and the following scales: Mattis Dementia Rating Scale (MDRS), semantic and phonemic verbal fluency tests (VFT), Benton Visual Retention Test (BVRT), Stroop Test (STROOP), Clock drawing test (CLOCK), WAIS III Letter and Number sequencing (WAIS III LN), Rey Auditory Verbal Learning Test (RAVLT) and Benton Judgement of Line Orientation Test (BJLOT). Motor status was assessed by UPDRS III.
Results: Motor status: Patients 1, 2 and 3 present mild to moderate Parkinson disease of 7, 8 and 3years of evolution respectively, patient 4 is asymptomatic. Cognitive status: Patient 2 and 3 both refer cognitive decline while patient 1 presents no cognitive complaints, however they all show a progressive cognitive decline across various tasks. Tests of frontal function showed the first alterations in all patients but fluctuate. The first cognitive complaints coincide with deterioration of tasks of posterior cortical basis. Patient 4 presents a normal performance on all tests. Patient 1, 2 and 3 have all presented visual hallucinations.
Conclusions: A fluctuating frontal impairment is observed at early stages. Prominent visuospatial alterations and visual hallucinations suggest that posterior cortical dysfunction might be a distinct early feature of the cognitive impairment observed in patients with this mutation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2011.07.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DOPAC as a modulator of α-Synuclein and E46K interactions with membrane: Insights into binding dynamics.
Int J Biol Macromol
January 2025
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy. Electronic address:
α-Synuclein (Syn) is an intrinsically disordered protein, abundant in presynaptic neurons. It is a constituent of the Lewis Body inclusions as amyloid fibrils, in Parkinson's disease patients. It populates an ensemble of conformations and floats between the free random coil and the membrane-bound α-helical species.
View Article and Find Full Text PDFIncreased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease.
bioRxiv
September 2024
Department of Neurology, Robert Wood Johnson Medical School, Institute for Neurological Therapeutics at Rutgers, Rutgers Biomedical and Health Sciences, Piscataway, NJ 08854, USA.
Article Synopsis
- * Researchers identified 38 genes that influence αSyn propagation, focusing on two genes, which help understand how αSyn interacts with lipids and forms inclusions resembling Lewy Bodies.
- * Analysis of gene expression changes after manipulating these genes revealed a connection to increased risk variants in Parkinson's patients, supporting a model where genetic factors disrupt αSyn regulation, leading to disease progression.
Structurally targeted mutagenesis identifies key residues supporting -synuclein misfolding in multiple system atrophy.
bioRxiv
July 2024
Department of Biology and Institute for Applied Life Sciences, University of Massachusetts Amherst, Amherst, MA, USA.
Multiple system atrophy (MSA) and Parkinson's disease (PD) are caused by misfolded -synuclein spreading throughout the central nervous system. While familial PD is linked to several point mutations in -synuclein, there are no known mutations associated with MSA. Our previous work investigating differences in -synuclein misfolding between the two disorders showed that the familial PD mutation E46K inhibits replication of MSA prions both and providing key evidence to support the hypothesis that -synuclein adopts unique strains in patients.
View Article and Find Full Text PDFImmunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
Sci Transl Med
March 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
Despite the advances in cancer treatment achieved, for example, by the CD20 antibody rituximab, an urgent medical need remains to optimize the capacity of such antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) that determines therapeutic efficacy. The cytokine IL-15 stimulates proliferation, activation, and cytolytic capacity of NK cells, but broad clinical use is prevented by short half-life, poor accumulation at the tumor site, and severe toxicity due to unspecific immune activation. We here report modified immunocytokines consisting of Fc-optimized CD19 and CD20 antibodies fused to an IL-15 moiety comprising an L45E-E46K double mutation (MIC format).
View Article and Find Full Text PDFCalmodulinopathy in Japanese Children - Their Cardiac Phenotypes Are Severe and Show Early Onset in Fetal Life and Infancy.
Circ J
November 2023
Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center.
Article Synopsis
- Cardiac calmodulinopathy is a rare genetic condition that leads to dangerous heart rhythms and sudden death in young people, linked to mutations in calmodulin genes (CALM1, CALM2, CALM3).
- Researchers analyzed 195 children suspected of inherited heart conditions and found 10 with gene variants associated with calmodulinopathy, presenting various arrhythmia-related symptoms.
- Effective treatment options included beta-blockers, often combined with other medications, highlighting the importance of early diagnosis and intervention for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!